Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

DOI Full Paper Access

31

Citations

13

References

2019

Year

Francisco J. Esteva, Y. Baranau, V. Baryash, Alexey Manikhas, Vladimir Moiseyenko, Giorgi Dzagnidze, Edvard Zhavrid, Dmytro Boliukh, Daniil Stroyakovskiy, Joanna Pikiel,

Cancer Chemotherapy and Pharmacology

Abstract

Adjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1 year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.

References

	Year	Citations

Page 1